Tracking tumor DNA in the blood of people with neuroblastoma
Follows tumor DNA in the blood of people with neuroblastoma over time.
Plain-language title generated from the registry record
Registry title: Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
Key facts
- Where
- Guangzhou, ChinaSee the site
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT07516678
- Record updated
- 8 April 2026
- Original description
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma. The study aims to characterize baseline genomic alterations, assess ctDNA detectability and dynamic changes during treatment and follow-up, compare tumor-informed personalized MRD assays with fixed-panel assays, and determine the clinical utility of ctDNA/MRD for treatment response assessment, molecular remission evaluation, relapse surveillance, and early detection of disease progression.Read full original descriptionShow less
A Prospective Observational Study of Serial Circulating Tumor DNA and Molecular Residual Disease Monitoring for Molecular Profiling, Treatment Response Assessment, and Early Relapse Detection in Patients With Neuroblastoma
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma. The study aims to characterize baseline genomic alterations, assess ctDNA detectability and dynamic changes during treatment and follow-up, compare tumor-informed personalized MRD assays with fixed-panel assays, and determine the clinical utility of ctDNA/MRD for treatment response assessment, molecular remission evaluation, relapse surveillance, and early detection of disease progression.
Inclusion: Patients with histologically or clinically confirmed neuroblastoma according to institutional or protocol-defined diagnostic criteria; Newly diagnosed, relapsed, refractory, or progressive neuroblastoma eligible for serial biospecimen collection during routine clinical care; Availability of peripheral blood samples for ctDNA/MRD analysis at baseline and/or longitudinal follow-up time points; Availability of clinical data required for molecular-clinical correlation analyses, including response and outcome assessment; Availability of tumor tissue and matched control samples for tumor-informed assay development, if applicable and feasible; Written informed consent from a parent or legal guardian, and assent from the participant when applicable.
Exclusion: Inability to provide protocol-required blood samples for ctDNA/MRD testing. Insufficient clinical information for protocol-defined response or outcome analyses; Poor-quality or insufficient biospecimens that preclude molecular analysis, when molecular testing is a required component of the study dataset; Any condition that, in the opinion of the investigator, would make study participation inappropriate.